Entero Healthcare Solutions announced robust Q4 FY26 results, exceeding revenue growth targets with a 31.5% like-for-like increase and achieving a 4% EBITDA margin. The company highlighted significant strides in its PAN-India distribution platform, serving over 100,000 pharmacies and 3,600 hospitals. Strategic MedTech expansion and operational efficiencies are driving performance, with guidance for FY27 projecting 23% consolidated revenue growth and a focus on profitable expansion.
Entero Healthcare Solutions Reports Strong Q4 FY26 Performance
Entero Healthcare Solutions Limited hosted its Q4 FY26 Earnings Conference Call on May 26, 2026, detailing a year of substantial growth and strategic expansion. The company reported exceeding its financial guidance for the full year, driven by a strong performance in the fourth quarter.
Full Year Financial Highlights (FY26)
For the full fiscal year 2026, Entero Healthcare Solutions achieved a like-for-like revenue growth of 31.5%, reaching INR 6,591 crores. Organic growth stood at 15.6%, complemented by 16% inorganic growth. The company met its EBITDA margin target, delivering 4%, with EBITDA at INR 266 crores. Gross profit saw a 40% year-on-year increase to INR 680 crores, and Net Profit After Tax (PAT) grew by 36% to INR 146 crores, with a PAT margin of 2.2%. Operating cash flow for the full year was INR 96.2 crores.
Quarter 4 FY26 Performance
The fourth quarter of FY26 demonstrated strong momentum, with revenue growing 42.6% year-on-year. Organic growth was 17.1%, with acquisitions contributing an additional 26%. Gross margin expanded by 110 basis points to 10.9%, leading to a 59% year-on-year increase in gross profit to INR 207 crores. EBITDA margin stood at 4.5%, a 85 basis points increase year-on-year, with EBITDA growing by 76% to INR 86 crores. PAT grew by 44% to INR 45.1 crores, with a PAT margin of 2.4%.
Strategic Expansion and Future Outlook (FY27 Guidance)
Entero Healthcare Solutions has successfully closed 7 acquisitions during the year, including 3 in the MedTech segment, significantly scaling its presence in diagnostics, cardiology, and consumables. The MedTech segment now contributes over INR 1,000 crores in annualized revenue. For the upcoming fiscal year 2027, the company has set a guidance for a consolidated revenue growth of 23% year-on-year, excluding any new acquisitions. The company aims for a 5% EBITDA margin and a strong EBITDA to operating cash flow conversion ratio of at least 50%.
Key Discussion Points from the Earnings Call
Minority Interest Explained
Management addressed a significant jump in minority interest in Q4 FY26, attributing it to an abnormal contribution from a subsidiary where the company held a partial stake. This is expected to normalize in the coming year, with minority interest projected to be around 25% to 27% of PAT for FY27, down from approximately 38% in Q4 FY26.
MedTech Segment Growth
The MedTech segment is a key focus, with current revenue contribution exceeding INR 1,000 crores. The company sees substantial opportunities in imaging, neuropsychiatry, orthopedics, and cardiology. MedTech is expected to contribute up to 20% of the business in the future, offering higher margins due to a more commercial role, including demand generation and sales.
GLP-1 Drug Market
Entero Healthcare Solutions is positioned to benefit from the generic GLP-1 drug market, with sales contributing approximately INR 10-12 crores per month, estimated at 5% of the overall industry value. The company’s existing cold chain infrastructure provides a competitive advantage in distributing these products.
Working Capital and Efficiency
The company is focused on optimizing its working capital cycle. The increase in payable days was mainly due to the higher MedTech contribution. For FY27, they anticipate an EBITDA to operating cash flow conversion of at least 50%, reflecting improved operational efficiencies and working capital rationalization.
Acquisition Strategy
Entero Healthcare Solutions emphasized a strategic approach to acquisitions, with a focus on organic growth for the next 6-8 months. While not actively pursuing new deals immediately, they maintain an openness to opportunities that create shareholder value. Key management personnel remain with acquired companies post-acquisition, ensuring continuity and smooth integration.
Gross Margin Drivers
Improvements in gross margins are attributed to the company’s scale, allowing for better purchasing economics, and its increasing role as a commercial partner for manufacturers. This commercial role, involving demand generation and end-to-end services, yields higher margins compared to a pure fulfillment model.
Source: BSE
